IBDEI218 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,34053,0)
 ;;=N05.0^^154^1722^50
 ;;^UTILITY(U,$J,358.3,34053,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34053,1,3,0)
 ;;=3^Nephritic syndrome unspec w/ minor glomerular abnormality
 ;;^UTILITY(U,$J,358.3,34053,1,4,0)
 ;;=4^N05.0
 ;;^UTILITY(U,$J,358.3,34053,2)
 ;;=^5015541
 ;;^UTILITY(U,$J,358.3,34054,0)
 ;;=N05.1^^154^1722^49
 ;;^UTILITY(U,$J,358.3,34054,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34054,1,3,0)
 ;;=3^Nephritic syndrome unspec w/ focal & segmental glomerular lesions
 ;;^UTILITY(U,$J,358.3,34054,1,4,0)
 ;;=4^N05.1
 ;;^UTILITY(U,$J,358.3,34054,2)
 ;;=^5015542
 ;;^UTILITY(U,$J,358.3,34055,0)
 ;;=N05.2^^154^1722^46
 ;;^UTILITY(U,$J,358.3,34055,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34055,1,3,0)
 ;;=3^Nephritic syndrome unspec w/ diffuse membranous glomrlneph
 ;;^UTILITY(U,$J,358.3,34055,1,4,0)
 ;;=4^N05.2
 ;;^UTILITY(U,$J,358.3,34055,2)
 ;;=^5015543
 ;;^UTILITY(U,$J,358.3,34056,0)
 ;;=N05.3^^154^1722^47
 ;;^UTILITY(U,$J,358.3,34056,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34056,1,3,0)
 ;;=3^Nephritic syndrome unspec w/ diffuse mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,34056,1,4,0)
 ;;=4^N05.3
 ;;^UTILITY(U,$J,358.3,34056,2)
 ;;=^5015544
 ;;^UTILITY(U,$J,358.3,34057,0)
 ;;=N05.4^^154^1722^45
 ;;^UTILITY(U,$J,358.3,34057,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34057,1,3,0)
 ;;=3^Nephritic syndrome unspec w/ diffuse endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,34057,1,4,0)
 ;;=4^N05.4
 ;;^UTILITY(U,$J,358.3,34057,2)
 ;;=^5015545
 ;;^UTILITY(U,$J,358.3,34058,0)
 ;;=N05.5^^154^1722^48
 ;;^UTILITY(U,$J,358.3,34058,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34058,1,3,0)
 ;;=3^Nephritic syndrome unspec w/ diffuse mesangiocap glomrlneph
 ;;^UTILITY(U,$J,358.3,34058,1,4,0)
 ;;=4^N05.5
 ;;^UTILITY(U,$J,358.3,34058,2)
 ;;=^5015546
 ;;^UTILITY(U,$J,358.3,34059,0)
 ;;=N05.6^^154^1722^43
 ;;^UTILITY(U,$J,358.3,34059,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34059,1,3,0)
 ;;=3^Nephritic syndrome unspec w/ dense deposit disease
 ;;^UTILITY(U,$J,358.3,34059,1,4,0)
 ;;=4^N05.6
 ;;^UTILITY(U,$J,358.3,34059,2)
 ;;=^5015547
 ;;^UTILITY(U,$J,358.3,34060,0)
 ;;=N05.7^^154^1722^44
 ;;^UTILITY(U,$J,358.3,34060,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34060,1,3,0)
 ;;=3^Nephritic syndrome unspec w/ diffuse crescentic glomrlneph
 ;;^UTILITY(U,$J,358.3,34060,1,4,0)
 ;;=4^N05.7
 ;;^UTILITY(U,$J,358.3,34060,2)
 ;;=^5015548
 ;;^UTILITY(U,$J,358.3,34061,0)
 ;;=N05.8^^154^1722^51
 ;;^UTILITY(U,$J,358.3,34061,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34061,1,3,0)
 ;;=3^Nephritic syndrome unspec w/ oth morphologic changes
 ;;^UTILITY(U,$J,358.3,34061,1,4,0)
 ;;=4^N05.8
 ;;^UTILITY(U,$J,358.3,34061,2)
 ;;=^5134085
 ;;^UTILITY(U,$J,358.3,34062,0)
 ;;=N05.9^^154^1722^52
 ;;^UTILITY(U,$J,358.3,34062,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34062,1,3,0)
 ;;=3^Nephritic syndrome unspec w/ unspec morphologic changes
 ;;^UTILITY(U,$J,358.3,34062,1,4,0)
 ;;=4^N05.9
 ;;^UTILITY(U,$J,358.3,34062,2)
 ;;=^5134086
 ;;^UTILITY(U,$J,358.3,34063,0)
 ;;=N06.0^^154^1722^40
 ;;^UTILITY(U,$J,358.3,34063,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34063,1,3,0)
 ;;=3^Isolated proteinuria w/ minor glomerular abnormality
 ;;^UTILITY(U,$J,358.3,34063,1,4,0)
 ;;=4^N06.0
 ;;^UTILITY(U,$J,358.3,34063,2)
 ;;=^5015549
 ;;^UTILITY(U,$J,358.3,34064,0)
 ;;=N06.1^^154^1722^39
 ;;^UTILITY(U,$J,358.3,34064,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34064,1,3,0)
 ;;=3^Isolated proteinuria w/ focal & segmental glomerular lesions
 ;;^UTILITY(U,$J,358.3,34064,1,4,0)
 ;;=4^N06.1
